Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMSON1P)

Drug Name

D17.4 Drug Info

Synonyms

26482-53-1; 2-(1-adamantyl)ethanamine; 2-(adamantan-1-yl)ethanamine; 1-C-Ethylaminoadamantane; Tricyclo[3.3.1.13,7]decane-1-ethanamine; 1-Adamantanethylamine; 1-adamantaneethanamine; 2-Adamantan-1-yl-ethylamine; 2-adamantanylethylamine; Tricyclo(3.3.1.13,7)decane-1-ethanamine; PubChem21555; Enamine_005504; D-174; 2-(1-adamantyl)ethylamine; AC1L20RI; 2-(2-amino)ethyladamantane; Oprea1_362282; 2-(Adamant-1-yl)ethylamine; SCHEMBL973650; CHEMBL341013; Mrz-2/174; CTK1A4494; DTXSID50181075; MolPort-002-464-537

Indication

Disease Entry	ICD 11	Status	REF
Myasthenia gravis	8C6Y	Investigative	[1]

Cross-matching ID

TTD Drug ID: DMSON1P

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Immunoglobulin E (IgE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ligelizumab	DM103O8	Chronic idiopathic urticaria	EB00.1	Phase 3	[2]
MEMP1972A	DMUMCWS	Allergic rhinitis	CA08.0	Phase 2	[3]
Xmab-7195	DME7IVL	Asthma	CA23	Phase 1	[4]
PF-06444752	DM9UZTO	Asthma	CA23	Phase 1	[5]
MEDI4212	DMBI4EN	Asthma	CA23	Phase 1	[6]
AVP-13358	DM8CYJ1	Rhinitis	FA20	Phase 1	[7]
TAK-201	DM8S173	Allergy	4A80-4A85	Discontinued in Phase 2	[8]
TEI-9874	DMXM3B4	Allergy	4A80-4A85	Terminated	[9]
IGE-026	DM16S98	Allergic rhinitis	CA08.0	Terminated	[10]
IGEL1.2	DMOU234	Allergy	4A80-4A85	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Immunoglobulin E (IgE)	TTYJQTF	NOUNIPROTAC	Not Available	[1]

------------------------------------------------------------------------------------

References

1	Therapeutic applications of aptamers. Expert Opin Investig Drugs. 2008 Jan;17(1):43-60.
2	Clinical pipeline report, company report or official report of Novartis.
3	International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information, Vol. 25, No. 4, 2011
4	Clinical pipeline report, company report or official report of Xencor.
5	ClinicalTrials.gov (NCT01723254) A Study To Assess The Safety And Tolerability Of Different Doses Of PF-06444753 And PF-06444752 In Subjects With Allergic Rhinitis. U.S. National Institutes of Health.
6	A novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthma. MAbs. 2014 May-Jun;6(3):756-64.
7	Novel 2-(substituted phenyl)benzimidazole derivatives with potent activity against IgE, cytokines, and CD23 for the treatment of allergy and asthma. J Med Chem. 2004 Dec 16;47(26):6451-4.
8	Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside. Expert Opin Biol Ther. 2010 Jun;10(6):951-8.
9	Effect of TEI-9874, an inhibitor of immunoglobulin E production, on allergen-induced asthmatic model in rats. Eur J Pharmacol. 2000 Aug 25;402(3):287-95.
10	IgE inhibition as a therapy for allergic disease. Int Arch Allergy Immunol. 1999 Feb-Apr;118(2-4):112-5.